TABLE 4.
miRNA levels of CAC or CRC patients in different studies.
| miRNA name | Sample type | Disease | Control | Sample size | Expression states | Sensitivity (%) | Specificity (%) | References |
|---|---|---|---|---|---|---|---|---|
| miR-375 | Plasma | CAC | UC/UCD | UC/UCD/CAC: 37/2/6 | ↑ | Patel et al. (2015) | ||
| miR-21 | Plasma | CRC | UC | UC/CRC: 37/33 | ↑ | 94 | 100 | Ahmed Hassan et al. (2020) |
| miR-92a | Plasma | CRC | UC | UC/CRC: 37/33 | ↑ | 84 | 100 | Ahmed Hassan et al. (2020) |
| Feces | CRC | HC | CRC/HC: 29/29 | ↑ | 90 | 52 | Choi et al. (2019) | |
| Panel of (miR-223/miR-92a) | Plasma, feces | CRC | HC | CRC/HC: 62/40 | ↑/↑ | 97 | 75 | Chang et al. (2016) |
| miR-200b-3p | Tissue | UCD | UC | UCD/UC: 10/7 | ↑ | Lewis et al. (2017) | ||
| miR-144* | Feces | CRC | HC | CRC/HC: 29/29 | ↑ | 79 | 67 | Choi et al. (2019) |
↓ indicates inhibition/reduction of miRNA expression in the condition described in the corresponding "disease" and "sample type" item, while ↑ indicates increase/promotion; CAC, colitis-associated cancer; CRC, colorectal cancer; UC, ulcerative colitis; UCD, ulcerative colitis-associated dysplasia; HC, healthy control.